Linagliptin Hcs

Linagliptin, the active ingredient in Linagliptin Hcs, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is prescribed to improve glycaemic control in adults with type 2 diabetes mellitus. GNH USA supplies Linagliptin Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used in the management of type 2 diabetes mellitus, acting on the incretin pathway to improve glucose regulation.

Type 2 diabetes mellitus: improves overall glycaemic control as monotherapy or in combination with other antidiabetic agents. Adults with type 2 diabetes: reduces HbA1c levels when added to diet and exercise. Adjunct therapy in type 2 diabetes: enhances glucose control alongside metformin or sulfonylureas.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient mild to moderate head pain. - Upper respiratory tract infection: symptoms such as cough and sore throat. - Dizziness: occasional light‑headed sensation. - Back pain: occasional musculoskeletal discomfort. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes, requiring immediate medical attention. - Severe allergic reactions: anaphylaxis or angioedema presenting with swelling, rash, or breathing difficulty. - Stevens‑Johnson syndrome: rare skin eruption with blistering and mucosal involvement. - Hepatic injury: abnormal liver function tests indicating potential liver damage.

Linagliptin should be used with caution in specific clinical situations.

Renal impairment: dose adjustment may be required in patients with severe renal dysfunction. Hepatic impairment: monitor liver function tests in patients with existing liver disease. Cardiovascular disease: assess risk when combined with other glucose‑lowering agents. Hypoglycaemia risk: increased when used with sulfonylureas or insulin; monitor blood glucose closely. Pregnancy and breastfeeding: safety not established; avoid unless clearly needed. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Sulfonylureas (e.g., glimepiride): heightened risk of hypoglycaemia. - Insulin: additive glucose‑lowering effect may cause hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Rifampin: may reduce linagliptin plasma concentrations. - Digoxin: potential increase in digoxin levels. - Diuretics: may affect renal clearance of linagliptin, requiring monitoring.